AAV Tropism for Testicular Tissues

In testicular gene therapy, the target is often split between the interstitial space (where Leydig cells produce testosterone) and the seminiferous tubules (where Sertoli cells and germ cells like spermatogonia reside).

Because the blood-testis barrier (BTB) is one of the tightest in the body, the choice of AAV serotype and the injection route (interstitial vs. intratubular) are the primary factors for success.

Serotype	Target Cells	Tropism Level	Best Route	Key Applications
AAV8	Leydig Cells	Ultra High	Interstitial	The current “gold standard” for Leydig cell failure and testosterone restoration.
AAV9	Germ Cells & Sertoli	Very High	Intratubular	Recently identified as a premier vector for reaching the spermatogenic lineage (germ cells).
AAV1	Sertoli & Leydig	High	Either	Shows robust transduction in both compartments; often used for gene silencing (shRNA).
AAV2	Sertoli Cells	Moderate	Intratubular	One of the first studied; targets the “nursing” Sertoli cells but lacks high efficiency for germ cells.
AAV5	Sertoli Cells	Moderate	Intratubular	Useful for targeting the tubule lining; genetically distinct from AAV2-based vectors.
AAVrh10	General Testis	High	Systemic / Local	Broad tropism across the male reproductive tract; often used to bypass human pre-existing immunity.

Understanding the Two Compartments

To effectively target the testis, you must choose the injection route based on the cell type you need to reach:

1. Interstitial Injection:
   • Primary Target: Leydig Cells (located between the tubules).
   • Best Serotype: AAV8.
   • Use Case: Treating androgen deficiency or Leydig cell maturation issues. Interstitial delivery is relatively easy as it doesn’t require navigating the complex tubule network.
2. Intratubular (Seminiferous Tubule) Injection:
   • Primary Target: Sertoli Cells and Germ Cells (Spermatogonia).
   • Best Serotype: AAV9 or AAV1.
   • Use Case: Treating male infertility, azoospermia, or studying spermatogenesis. This route involves injecting via the efferent duct or directly into the rete testis to bypass the blood-testis barrier.

The Challenge of Germline Transmission

A unique ethical and safety concern for the testis is germline transmission (the risk of the therapy being passed on to offspring).

• Somatic Targeting: Most clinical researchers aim to target Sertoli or Leydig cells (somatic cells) specifically to avoid modifying the sperm itself.
• Germ Cell Targeting: In research settings, AAV9 has shown the ability to transduce the spermatogenic lineage, which is useful for creating transgenic animal models but requires strict ethical oversight in human applications.

Cell-Specific Promoters

To prevent unwanted expression in the liver or other organs if the virus “leaks” into the bloodstream:

• StAR: Restricts expression to Leydig Cells.
• WT1 or Sox9: Restricts expression to Sertoli Cells.
• Sycp1 / Stra8: Restricts expression strictly to Germ Cells (Spermatocytes/Spermatogonia).